Nanobiotix SA has appointed Bart Van Rhijn as its new chief financial officer as the company prepares for a registration study of its radioenhancer for patients with head and neck cancer. Mr Van Rhijn joins from Servier Pharmaceuticals LLC, the US unit of the French Servier Group where he was CFO. Prior to this, he held leadership roles at PricewaterhouseCoopers and Galderma SA of Switzerland. Mr Van Rhijn received masters’ degrees in civil law and tax law from Leiden University in the Netherlands and a master of business administration from the FW Olin Graduate School of Business at Babson College, US.
Nanobiotix announced the appointment on 1 June 2021.
Copyright 2021 Evernow Publishing Ltd